eprintid: 10205788 rev_number: 7 eprint_status: archive userid: 699 dir: disk0/10/20/57/88 datestamp: 2025-03-10 09:27:41 lastmod: 2025-03-10 09:27:41 status_changed: 2025-03-10 09:27:41 type: article metadata_visibility: show sword_depositor: 699 creators_name: Boeckhaus, Jan creators_name: Gale, Daniel P creators_name: Simon, James creators_name: Ding, Jie creators_name: Zhang, Yanqin creators_name: Bergmann, Carsten creators_name: Turner, A Neil creators_name: Hall, Matthew creators_name: Sayer, John A creators_name: Srivastava, Shalabh creators_name: Kang, Hee Gyung creators_name: Cerkauskaite-Kerpauskiene, Agne creators_name: Gillion, Valentine creators_name: Claes, Kathleen J creators_name: Krueger, Bastian creators_name: de Fallois, Jonathan creators_name: Walden, Ulrike creators_name: Choi, Mira creators_name: Schueler, Markus creators_name: Mueller, Roman-Ulrich creators_name: Todorova, Polina creators_name: Hohenstein, Bernd creators_name: Zeisberg, Michael creators_name: Friede, Tim creators_name: Knebelmann, Bertrand creators_name: Halbritter, Jan creators_name: Gross, Oliver title: SGLT2-Inhibition in Patients With Alport Syndrome ispublished: pub divisions: UCL divisions: B02 divisions: C10 divisions: D17 divisions: G93 keywords: Science & Technology, Life Sciences & Biomedicine, Urology & Nephrology, albuminuria, Alport syndrome, COL4, dapagliflozin, empagliflozin, kidney failure, SGLT2 INHIBITORS, EMPAGLIFLOZIN, DAPAGLIFLOZIN, INSIGHTS note: © 2024 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). abstract: Introduction: Large-scale trials showed positive outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in adults with chronic kidney disease (CKD). Whether the use of SGLT2i is safe and effective in patients with the common hereditary CKD Alport syndrome (AS) has not yet been investigated specifically in larger cohorts. Methods: This observational, multicenter, international study (NCT02378805) assessed 112 patients with AS after start of SGLT2i. The study's primary end point was change of albuminuria in albumin/g creatinine from the start of therapy. Results: Compared to randomized trials investigating the effect of SGLT2i in CKD, the adult patients in this study were younger (aged 38 ± 14 years) and had a better estimated glomerular filtration rate (eGFR, 63 ± 35 ml/min per 1.73 m2; n = 98). Maximum follow-up was 32 months. Compared to baseline, at the first 3 follow-up visits (months 1 to 3, 4 to 8, and 9 to 15) after initiation of SGLT2i therapy, a significant reduction of albuminuria in mg albumin/g creatinine (>30%) was observed. Mean loss of eGFR was 9 ± 12 ml/min per 1.73 m2 almost 1 year after initiation of SGLT2i therapy (n = 35). At a total of 71 patient-years at risk, 0.24 adverse events (AEs) per patient-year on SGLT2i were reported. Conclusion: This study indicates that, additive to renin-angiotensin system (RAS)-inhibition (RASi), SGLT2i have the potential to reduce the amount of albuminuria in patients with AS. Future studies are needed to investigate the long-term effects of SGLT2i on CKD progression in patients with AS to assess whether the observed reduction in albuminuria translates to a delay in kidney failure (KF). date: 2024-12 date_type: published publisher: ELSEVIER SCIENCE INC official_url: https://doi.org/10.1016/j.ekir.2024.09.014 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 2328569 doi: 10.1016/j.ekir.2024.09.014 medium: Electronic-eCollection pii: S2468-0249(24)01942-9 lyricists_name: Gale, Daniel lyricists_id: DGALE18 actors_name: Gale, Daniel actors_id: DGALE18 actors_role: owner funding_acknowledgements: [Research program, University Medical Center, University of Goettingen] full_text_status: public publication: Kidney International Reports volume: 9 number: 12 pagerange: 3490-3500 pages: 11 event_location: United States issn: 2468-0249 citation: Boeckhaus, Jan; Gale, Daniel P; Simon, James; Ding, Jie; Zhang, Yanqin; Bergmann, Carsten; Turner, A Neil; ... Gross, Oliver; + view all <#> Boeckhaus, Jan; Gale, Daniel P; Simon, James; Ding, Jie; Zhang, Yanqin; Bergmann, Carsten; Turner, A Neil; Hall, Matthew; Sayer, John A; Srivastava, Shalabh; Kang, Hee Gyung; Cerkauskaite-Kerpauskiene, Agne; Gillion, Valentine; Claes, Kathleen J; Krueger, Bastian; de Fallois, Jonathan; Walden, Ulrike; Choi, Mira; Schueler, Markus; Mueller, Roman-Ulrich; Todorova, Polina; Hohenstein, Bernd; Zeisberg, Michael; Friede, Tim; Knebelmann, Bertrand; Halbritter, Jan; Gross, Oliver; - view fewer <#> (2024) SGLT2-Inhibition in Patients With Alport Syndrome. Kidney International Reports , 9 (12) pp. 3490-3500. 10.1016/j.ekir.2024.09.014 <https://doi.org/10.1016/j.ekir.2024.09.014>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10205788/1/SGLT2-Inhibition%20in%20Patients%20With%20Alport%20Syndrome.pdf